Inhibikase Therapeutics (IKT) Times Interest Earned (2020 - 2022)

Inhibikase Therapeutics (IKT) has reported Times Interest Earned for 6 consecutive years, with -$0.44 the latest figure, recorded in Q4 2025.

• In Q4 2025, Times Interest Earned changed N/A year-over-year to -$0.44; the TTM figure through Dec 2025 stood at -$1.64 (changed N/A YoY), while the FY2025 annual figure was -$1.64, down 78.59% from the prior year.
• Times Interest Earned advanced to -$0.44 in Q4 2025 per IKT's latest filing, from -$282.66 in the prior quarter.
• Across five years, Times Interest Earned topped out at $273.1 in Q4 2021 and bottomed at -$28478.0 in Q3 2021.
• Historically, Times Interest Earned has averaged -$2826.7 across 5 years, with a median of -$152.87 in 2023.
• On a YoY basis, Times Interest Earned climbed as much as 262.36% in 2021 and fell as far as 29463.13% in 2021.
• Inhibikase Therapeutics' Times Interest Earned stood at $273.1 in 2021, then slumped by 123.51% to -$64.2 in 2022, then plunged by 130.15% to -$147.76 in 2023, then surged by 74.27% to -$38.02 in 2024, then jumped by 98.86% to -$0.44 in 2025.
• Business Quant data shows IKT's Times Interest Earned at -$0.44 in Q4 2025, -$282.66 in Q2 2025, and -$7798.1 in Q1 2025.